Rationale for administering beta-blocker therapy to patients undergoing coronary artery bypass surgery: a systematic review. Issue 8 (3rd August 2018)

• Record Type: Journal Article
• Authors: Thaper, Arushi; Kulik, Alexander
• Is Part Of: Expert opinion on drug safety. Volume 17:Issue 8(2018)
• Page Start: 805
• Page End: 813
• Publication Date: 2018-08-03
• Subjects: Coronary artery disease -- myocardial infarction -- coronary artery bypass graft surgery -- beta-blockers -- efficacy -- safety; Drugs -- Side effects -- Periodicals; Drugs -- Toxicology -- Periodicals; Chemotherapy -- Periodicals; 615.704
• DOI: 10.1080/14740338.2018.1504019
• Languages: English
• ISSNs: 1474-0338

Abstract

ABSTRACT: Introduction : Secondary preventative therapies are essential for patients undergoing coronary artery bypass graft (CABG) surgery to optimize perioperative and long-term outcomes. Beta-blockers are commonly used to treat patients with coronary artery disease and congestive heart failure (CHF), but their role for CABG patients remains unclear. The goal of this systematic review was to evaluate the rationale for administering beta-blockers to the CABG population and to assess their efficacy before and after coronary surgical revascularization. Areas covered : A systematic literature review was performed to retrieve relevant articles from the PubMed database published between 1985 and 2017. Expert opinion : Outside of the surgical field, strong evidence supports the use of beta-blockers for patients with a history of previous myocardial infarction (MI) or CHF. For the CABG population, studies have suggested that perioperative beta-blocker therapy is beneficial, with an associated reduction in mortality, particularly among those with a history of previous MI or CHF. Beta-blocker administration has also clearly been shown to lower the rate of new-onset postoperative atrial fibrillation after CABG. Among the different types of beta-blockers, perioperative carvedilol appears to be the most beneficial. In the absence of contraindications, nearly all CABG patients are candidates for perioperative beta-blocker therapy.